Table 2 PI3k inhibition causes FOXO3a activation in breast cancer cells
From: Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review
First author (Year) | Treatment | Effect on FOXO3a (Activates/Inactivates) | Cellular effects |
|---|---|---|---|
Espinoza (2011) [25] | Zoledronic acid (ZOL) | Activates in MDA-MB-231 and MCF-7 measured by nuclear translocation of FOXO3a. | Inhibited proangiogenic factor, CCN1 in TNBC |
Guo (2004) [34] | Wortmannin, EGCG | Activates in MCF-7 and ZR-75 cells; and Hs578T and MDA-MB-231 cells, measured as FOXO3a expression and nuclear translocation. | Increased ER expression |